VALIDATION OF AN ALGORITHM TO IDENTIFY HR+/HER2-METASTATIC BREAST CANCER IN CLAIMS DATA

被引：0
|
作者：
Chin, A. [1 ]
Ip, Q. [1 ]
Wu, X. [1 ]
Lyle, D. [2 ]
机构：
[1] Komodo Hlth, San Francisco, CA USA
[2] NeoGenomics, Ft Myers, FL USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH56
引用
收藏
页码：S163 / S163
页数：1
相关论文
共 50 条
  • [21] Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2-Metastatic Breast Cancer
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    ADVANCES IN THERAPY, 2018, 35 (06) : 768 - 778
  • [22] Treatment patterns and characteristics of postmenopausal women with HR+/HER2-metastatic breast cancer receiving everolimus
    Vekeman, Francis
    Hao, Yanni
    Cheng, Wendy Y.
    Fortier, Jonathan
    Robitaille, Marie-Noelle
    Duh, Mei Sheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 114 - 115
  • [23] Initial real world treatment patterns and outcomes of Abemaciclib for the treatment of HR+,HER2-metastatic breast cancer
    Carter, Gebra Cuyun
    Sheffield, Kristin M.
    Gossai, Anala
    Huang, Yu-Jing
    Zhu, Yajun Emily
    Bowman, Lee
    Smith, Emily Nash
    Mathur, Raina
    Cohen, Aaron B.
    Baxi, Shrujal
    Rybowski, Sarah
    Chong, Amy Lee
    Seidman, Andrew D.
    CANCER RESEARCH, 2020, 80 (04)
  • [24] Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2-metastatic breast cancer
    Goyal, R. K.
    Carter, G. C.
    Nagar, S. N.
    Smyth, E. N.
    Price, G. L.
    Huang, Y-J
    Bromund, J. L.
    Li, L.
    Schilder, J. M.
    Davis, K. L.
    Kaye, J. A.
    CANCER RESEARCH, 2017, 77
  • [25] ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
    Venetis, Konstantinos
    Pepe, Francesco
    Pescia, Carlo
    Cursano, Giulia
    Criscitiello, Carmen
    Frascarelli, Chiara
    Mane, Eltjona
    Russo, Gianluca
    Salimbeni, Beatrice Taurelli
    Troncone, Giancarlo
    Rocco, Elena Guerini
    Curigliano, Giuseppe
    Fusco, Nicola
    Malapelle, Umberto
    CANCER TREATMENT REVIEWS, 2023, 121
  • [26] Physician experiences and preferences in the treatment of HR+/HER2-metastatic breast cancer in the United States: aphysician survey
    Lin, Peggy L.
    Hao, Yanni
    Xie, Jipan
    Li, Nanxin
    Zhong, Yichen
    Zhou, Zhou
    Signorovitch, James E.
    Wu, Eric Q.
    CANCER MEDICINE, 2016, 5 (02): : 209 - 220
  • [27] Real-world study of patients with HR+/ HER2-metastatic breast cancer treated with palbociclib and fulvestrant
    Robert, Nicholas
    Chen, Connie
    Doan, Justin
    Venkatasetty, Divea
    Espirito, Janet L.
    Aguilar, Kathleen M.
    FUTURE ONCOLOGY, 2025, 21 (01) : 83 - 94
  • [28] Frontline Fulvestrant, Palbociclib Combo Is Effective for Endocrine-Sensitive, HR+/HER2-Metastatic Breast Cancer
    不详
    ONCOLOGY-NEW YORK, 2020, 34 (11): : 486 - 486
  • [29] Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2-metastatic breast cancer
    Cuyun Carter, Gebra
    Sheffield, Kristin M.
    Gossai, Anala
    Huang, Yu-Jing
    Zhu, Yajun Emily
    Bowman, Lee
    Nash Smyth, Emily
    Mathur, Raina
    Cohen, Aaron B.
    Rasmussen, Erik
    Balakrishna, Shreya
    Morato Guimaraes, Claudia
    Rybowski, Sarah
    Seidman, Andrew D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (07) : 1179 - 1187
  • [30] VIRTUAL COMMUNITY ENGAGEMENT AMONG WOMEN RECEIVING PALBOCICLIB FOR HR+/HER2-METASTATIC BREAST CANCER: DATA FROM THE MADELINE STUDY
    Richardson, D.
    Zhan, L.
    Reynolds, M.
    Odom, D.
    McRoy, L.
    Mitra, D.
    Zelnak, A.
    Jones, C.
    VALUE IN HEALTH, 2019, 22 : S527 - S527
12345